Goldman Sachs Group Inc. Invests $685,000 in Rezolute, Inc. $RZLT

Goldman Sachs Group Inc. bought a new position in shares of Rezolute, Inc. (NASDAQ:RZLT) in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The fund bought 236,209 shares of the company’s stock, valued at approximately $685,000. Goldman Sachs Group Inc. owned 0.28% of Rezolute at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in RZLT. Jeppson Wealth Management LLC bought a new position in shares of Rezolute during the 1st quarter worth approximately $35,000. Paloma Partners Management Co bought a new position in shares of Rezolute during the 1st quarter worth approximately $48,000. XTX Topco Ltd bought a new position in shares of Rezolute during the 1st quarter worth approximately $95,000. Pale Fire Capital SE boosted its stake in shares of Rezolute by 9.1% during the 1st quarter. Pale Fire Capital SE now owns 47,122 shares of the company’s stock worth $137,000 after acquiring an additional 3,935 shares during the period. Finally, American Century Companies Inc. boosted its stake in shares of Rezolute by 5.2% during the 1st quarter. American Century Companies Inc. now owns 67,925 shares of the company’s stock worth $197,000 after acquiring an additional 3,334 shares during the period. 82.97% of the stock is currently owned by institutional investors.

Rezolute Price Performance

Shares of NASDAQ RZLT opened at $8.81 on Thursday. The stock has a market capitalization of $800.04 million, a PE ratio of -9.08 and a beta of 0.03. The business has a fifty day moving average price of $6.82 and a two-hundred day moving average price of $4.82. Rezolute, Inc. has a fifty-two week low of $2.21 and a fifty-two week high of $9.02.

Rezolute (NASDAQ:RZLT) last announced its quarterly earnings data on Wednesday, September 17th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.03). On average, equities analysts expect that Rezolute, Inc. will post -0.93 EPS for the current year.

Wall Street Analysts Forecast Growth

RZLT has been the subject of several recent research reports. Wedbush restated an “outperform” rating and issued a $12.00 price target on shares of Rezolute in a research note on Thursday, September 18th. Maxim Group boosted their price target on Rezolute from $15.00 to $20.00 and gave the company a “buy” rating in a research note on Thursday, September 18th. Guggenheim restated a “buy” rating and issued a $15.00 price target on shares of Rezolute in a research note on Monday. BTIG Research restated a “buy” rating and issued a $17.00 price target on shares of Rezolute in a research note on Thursday, September 18th. Finally, HC Wainwright restated a “buy” rating and issued a $14.00 price target on shares of Rezolute in a research note on Wednesday, September 3rd. One analyst has rated the stock with a Strong Buy rating and six have issued a Buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $14.50.

Rezolute Profile

Rezolute, Inc, a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder.